Osteoarthritis Flashcards

(82 cards)

1
Q

It is a common, progressive disorder affecting primarily weightbearing diarthrodial joints

A

Osteoarthritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Osteoarthritis is characterized by:

A
  • progressive deterioration and loss of articular cartilage
  • osteophyte formation
  • pain
  • limitation of motion
  • deformity
  • disability
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Idiopathic Osteorarthritis is also known as:

A

Primary OA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

T/F:

Trauma, metabolic or endocrine disorders, and congenital disorders are the known cause of Secondary OA?

A
  • True
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Risk factors for OA:

A
  • increasing age
  • obesity
  • repetitive use through work or leisure
    activities
  • joint trauma
  • genetic predisposition
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

ESR for the diagnosis of Hip OA?

A
  • less than 20 mm/h
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Age more than 50 years, morning stiffness
lasting 30 minutes or less, crepitus on motion, bony enlargement, bony
tenderness, and/or, palpable joint warmth are the symptoms needed for the diagnosis of what kind of OA?

A
  • Knee OA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

T/F:
ESR may be slightly elevated if inflammation is present. Rheumatoid factor is negative.
Analysis of synovial fluid reveals high viscosity and mild leukocytosis (<2000 white
blood cells/mm3 [<2 × 109
/L]) with predominantly mononuclear cells are the signs associated with OA?

A
  • True
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

T/F:
The goals of treatment for OA are: (1) educate patient, family members, and caregivers; (2) relieve
pain and stiffness; (3) maintain or improve joint mobility; (4) limit functional impairment; and (5) maintain or improve quality of life.

A
  • True
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

T/F:

Drug therapy for OA is targeted at relief of pain?

A
  • True
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Preferred first-line treatment for Knee and Hip OA?

A
  • Acetaminophen
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Acetaminophen is much effective than NSAIDs. Also, has less risk of serious gastrointestinal (GI) and cardiovascular events.

A
  • Acetaminophen is less effective than NSAIDs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Advantage of COX-2 inhibitors than non-selective NSAIDs in the treatment of OA?

A
  • less

risk for adverse GI events than nonselective NSAIDs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Drug that reduces adverse GI events in patients
taking NSAIDs?
CLUE: PGE1

A
  • Misoprostol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Drug that reduces adverse GI events in patients

taking NSAIDs?

A
  • Proton pump inhibitors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

COX-2 inhibitors may not be sustained beyong?

A
  • 6 months
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

For knee OA, it is the recommended medication if acetaminophen fails?

A
  • Topical NSAIDs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Topical NSAIDs are preferred than Oral NSAIDs in what patient age?

A
  • older than 75 years old
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Advantage of Topical NSAIDs compared to Oral NSAIDs in Knee OA?

A
  • fewer adverse GI events
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

A drug that is recommended for both hip and
knee OA when analgesia with acetaminophen or NSAIDs is suboptimal?
CLUE: corticosteroid injection, but what route?

A
  • Intra-articular corticosteroid injection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

T/F:
IA corticosteroid injections should not be administered more frequently than once every 3 months to minimize adverse effects?

A
  • True
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Criteria for using Tramadol as a treatment for Hip and knee OA?

A
  • patients who have failed scheduled full-dose acetaminophen and topical NSAIDs
  • who are not appropriate candidates for oral NSAIDs
  • who are not able to receive IA corticosteroids.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Criteria for using Opioids as a treatment OA?

A
  • patients not responding adequately to nonpharmacologic and first-line pharmacologic therapies
  • Patients who are at high surgical risk
    and cannot undergo joint arthroplasty are also candidates for opioid therapy.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

T/F:
Adverse
events limit routine use of opioids for treatment of OA pain.

A
  • True
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Adjunctive treatment in patients with partial response to | first-line analgesics (acetaminophen, oral NSAIDs).
- Duloxetine
26
preferred second-line | medication in patients with both neuropathic and musculoskeletal OA pain
- Duloxetine
27
Not routinely recommended for knee OA pain.
IA hyaluronic acid
28
T/F: Injections do not provide clinically meaningful improvement and may be associated with serious adverse events (eg, increased pain, joint swelling, and stiffness).
- True
29
T/F: lucosamine and/or chondroitin and topical rubefacients (eg, methyl salicylate, trolamine salicylate) lack uniform efficacy for hip and knee pain and are not preferred treatment options.
- True
30
first-line option for hand OA
- Topical NSAIDs
31
alternative first-line treatment for patients who cannot tolerate the local skin reactions or who received inadequate relief from topical NSAIDs.
- Oral NSAIDs
32
alternative first-line treatment and demonstrates modest improvement in pain scores. It is a reasonable option for patients unable to take oral NSAIDs. Adverse effects are primarily skin irritation and burning.
- Capsaicin creams
33
T/F: Use of nonprescription combination products containing acetaminophen and NSAIDs is discouraged because of increased risk of renal failure.
- True
34
T/F: NSAIDs may cause gastric and duodenal ulcers and bleeding through direct (topical) or indirect (systemic) mechanisms.
- True
35
Risk factors for NSAID-associated ulcers and ulcer complications (perforation, gastric outlet obstruction, and GI bleeding)
``` - history of complicated ulcer - concomitant use of multiple NSAIDs (including aspirin) or anticoagulants - use of high-dose NSAIDs - age more than 70 years. ```
36
Options for reducing the GI risk of nonselective NSAIDs:
- the lowest dose possible and only when needed - misoprostol four times daily with the NSAID - a PPI or full dose H2 -receptor antagonist daily with the NSAID
37
T/F: | All nonselective NSAIDs inhibit COX-1–dependent thromboxane production in platelets, thereby reducing bleeding risk.
- False (Increasing bleeding risk)
38
T/F: | NSAIDs should not be given in late pregnancy due to risk of premature closure of ductus arteriousus?
- True
39
The most potentially serious drug interactions include use of NSAIDs:
- Lithium - Warfarin - Oral hypoglycemics - Methotrexate - Antihypertensives - ACE-inhibitors - B-blockers - Diuretics
40
The most serious adverse event associated with Tramadol?
- Seizures
41
T/F: There is increased risk of serotonin syndrome when tramadol is used with other serotonergic medications, including duloxetine.
- True
42
Brand name: | Sodium hyaluronate 20 mg/2 mL: once weekly for five injections
- (Hyalgan)
43
Brand name: | Sodium hyaluronate 20 mg/2 mL: once weekly for three injections
- (Euflexxa)
44
Brand name: | Sodium hyaluronate 25 mg/2.5 mL: once weekly for five injections
- (Supartz)
45
Brand name: | Hylan polymers 16 mg/2 mL: once weekly for three injections
- (Synvisc)
46
Brand name: Hylan polymers 48 mg/6 mL: single injection (with efficacy for up to 26 weeks)
- (Synvisc-One)
47
Hyaluronan 30 mg/2 mL: once weekly for three injections
- (Orthovisc)
48
T/F: Depending on the joint(s) affected, measurement of grip strength and 50-ft walking time can help assess hand and hip/knee OA, respectively
- True
49
T/F: Obtain baseline serum creatinine, hematology profile, and serum transaminases with repeat levels at 6- to 12-month intervals to identify specific toxicities to the kidney, liver, GI tract, or bone marrow.
- True
50
Starting dose of Acetaminophen? (UR: 325–650 mg every 4–6 h or 1 g 3–4 times/ day)
325–500 mg 3 times | a day
51
Starting dose of Tramadol? (UR: Titrate dose in 25-mg increments to reach a maintenance dose of 50–100 mg 3 times a day)
25 mg in the morning
52
Starting dose of Tramadol ER? (UR: Titrate to 200–300 mg daily)
100 mg daily
53
Starting dose of Hydrocodone/ acetaminophen? (UR: 2.5–10 mg/325–650 mg 3–5 times daily)
5 mg/325 mg 3 times | daily
54
Starting dose of Oxycodone/ acetaminophen? (UR: 2.5–10 mg/325–650 mg 3–5 times daily)
5 mg/325 mg 3 times | daily
55
Usual range for Capsaicin 0.025% or | 0.075%
Apply to affected joint 3–4 times per day.
56
Usual range for Diclofenac 1% gel
Apply 2 or 4 g per site as prescribed, 4 | times daily.
57
Usual range for Diclofenac 1.3% | patch
Apply one patch twice daily to the site to | be treated, as directed.
58
Usual range for Diclofenac 1.5% | solution
Apply 40 drops to the affected knee, applying and rubbing in 10 drops at a time. Repeat for a total of 4 times daily
59
Starting dose for Triamcinolone? (UR: 10–40 mg per large joint (knee, hip, shoulder))
5–15 mg per joint
60
Starting dose for Methylprednisolone | acetate? (UR: 20–80 mg per large joint (knee, hip, shoulder))
10–20 mg per joint
61
Starting dose for Aspirin (plain, buffered, or enteric coated)? (UR: 325–650 mg 4 times a day)
325 mg 3 times a day
62
Starting dose for Celecoxib? (UR: 100 mg twice daily or 200 mg daily)
100 mg daily
63
Starting dose for Diclofenac IR? (UR: 50–75 mg twice a day)
50 mg twice a day
64
Starting dose for Diclofenac XR? (UR: 100–200 mg daily)
100 mg daily
65
Starting dose for Diflunisal? (UR: 500–750 mg twice a day)
250 mg twice a day
66
Starting dose for Etodolac? (UR: 400 to 500 mg twice a day)
300 mg twice a day
67
Starting dose for Fenoprofen? (UR:400–600 mg 3–4 times a day)
400 mg 3 times a day
68
Staring dose for Flurbiprofen? (UR: 200–300 mg/day in 2–4 divided doses)
100 mg twice a day
69
Staring dose for Ibuprofen? (UR: 1200–3200 mg/day in 3–4 divided doses)
200 mg 3 times a day
70
Starting dose for Indomethacin? (Titrate dose by 25–50 mg/day until pain controlled or maximum dose of 50 mg 3 times a day)
25 mg twice a day
71
Starting dose for Indomethacin SR? (UR: Can titrate to 75 mg SR twice daily if needed)
75 mg SR once daily
72
Starting dose for Ketoprofen?(UR: 50–75 mg 3–4 times a day)
50 mg 3 times a day
73
Starting dose for Meclofenamate? (UR: 50–100 mg 3–4 times a day)
50 mg 3 times a day
74
Staring dose for Mefenamic acid? (UR:250 mg 4 times a day)
250 mg 3 times a day
75
Starting dose for Meloxicam? (UR: 15 mg daily)
7.5 mg daily
76
Starting dose for Nabumetone? (UR: 500–1000 mg 1–2 times a day)
500 mg daily
77
Starting dose for Naproxen? (UR: 500 mg twice a day)
250 mg twice a day
78
Starting dose for Naproxen sodium? (UR: 220–550 mg twice a day)
220 mg twice a day
79
Starting dose for Naproxen sodium CR? (UR: 500–1500 mg once daily)
750–1000 mg once | daily
80
Staring dose for Oxaprozin?(UR: 600–1200 mg daily)
600 mg daily
81
Starting dose for Piroxicam? (UR: 20 mg daily)
10 mg daily
82
Starting dose for Salsalate? (UR: 500–1000 mg 2–3 times a day)
500 mg twice a day